The Incidence and Factors Related to the Musculoskeletal Adverse Events after COVID-19 Vaccination in Adults at Nopparat Rajathanee Hospital Service Unit
Keywords:
COVID-19 vaccines, Adverse events, Musculoskeletal systemAbstract
Background: The musculoskeletal system is most frequently affected by the COVID-19 vaccine adverse events. However few studies focus on the risk factors related to these adverse effects. Objective: To study the incidence and risk factors for musculoskeletal adverse events after the COVID-19 vaccination in adults. Method: Ethiognosis research using case-control design among 302,700 people who received the COVID-19 vaccination and were more than 18 years of age at the Nopparat Rajathanee Hospital service unit from 22 March 2021 to 31 December 2022. Information was derived from the database of the Ministry of Public Health. Among those who experienced musculoskeletal adverse events (22,539 cases) and those who did not experience adverse events (280,161 cases), risk was analyzed with logistic regression, presented as a multivariable odds ratio. Result: The incidence of musculoskeletal adverse events after the COVID-19 vaccination in adults was 7.45%. The statistically significant risk factors include: 1) Female gender (OR 1.65; 95%CI: 1.60, 1.70) 2) Age less than 50 years (OR 2.06; 95%CI: 1.98, 2.13) 3) Comorbidity: respiratory disease (OR 1.58; 95%CI: 1.45, 1.73) cardiovascular disease (OR 1.45; 95%CI:1.26, 1.67) cancer (OR 1.58; 95%CI: 1.31, 1.90) diabetes mellitus (OR 1.26; 95%CI:1.14, 1.39) and obesity (OR 1.53; 95%CI: 1.37, 1.72) 4) Vaccine types: Moderna® (OR 6.63; 95%CI:4.01, 10.94), Astrazeneca® (OR 1.60; 95%CI: 1.52, 1.68), Pfizer® (OR 1.30; 95%CI: 1.22, 1.39) 5) Five or more vaccinations (OR 9.33; 95%CI: 6.54, 13.32) Conclusion: Adults who received the COVID-19 vaccination that may have the potential to musculoskeletal adverse events include those who are a-female less than 50 years of age and those who have exhibited chronic respiratory disease, cardiovascular disease, cancer, diabetes mellitus, obesity and those who have received five or more doses of the vaccine.
References
Lopez Bernal J, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ 2021;373:n1088.
Department of disease control [Internet]. Nonthaburi: Department of disease control; 2021 [cited 21 Mar 2023]. Available from : https://ddc.moph.go.th/vaccine-covid19/pages/
Granados Villalpando JM, Romero Tapia SJ, Baeza Flores GDC, Ble Castillo JL, Juarez Rojop IE, Lopez Junco FI, et al. Prevalence and risk factors of adverse effects and allergic reactions after COVID-19 vaccines in a Mexican Population: an analytical cross-sectional study. Vaccines (Basel) 2022;10(12):2012.
Park YH, Kim MH, Choi MG, Chun EM. Correlation between COVID-19 vaccination and inflammatory musculoskeletal disorders. Medrxiv 2023;1-26.
Kitagawa H, Kaiki Y, Sugiyama A, Nagashima S, Kurisu A, Nomura T, et al. Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan. J Infect Chemother 2022;28(4):576-81.
Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID symptom study app in the UK: a prospective observational study. Lancet Infect Dis 2021;21(7):939-49.
Mori M, Yokoyama A, Shichida A, Sasuga K, Maekawa T, Moriyama T. Impact of sex and age on vaccine-related side effects and their progression after booster mRNA COVID-19 vaccine. Sci Rep 2023;13(1):19328.
Rai A, Aashish, Priya, Karmani S, Abbas W, Khatri G. Prevalence of rheumatoid arthritis following COVID-19 vaccine: An autoimmune disorder. Ann Med Surg (Lond) 2022;82:104628.
Maliwankul K, Boonsri P, Klabklay P, Chuaychoosakoon C. Shoulder injury related to COVID-19 vaccine administration: a case series. Vaccines (Basel). 2022;10(4):588.
Lamprinou M, Sachinidis A, Stamoula E, Vavilis T, Papazisis G. COVID-19 vaccines adverse events: potential molecular mechanisms. Immunol Res 2023;71(3):356-72.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Department of Medical Services, Ministry of Public Health
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
บทความที่ได้รับการตีพิมพ์เป็นลิขสิทธิ์ของกรมการแพทย์ กระทรวงสาธารณสุข
ข้อความและข้อคิดเห็นต่างๆ เป็นของผู้เขียนบทความ ไม่ใช่ความเห็นของกองบรรณาธิการหรือของวารสารกรมการแพทย์
